Gilead Under Investor Scrutiny

Why it matters

Gilead's financial landscape is buoyed by its dominant HIV franchise, with drugs like Biktarvy and Descovy consistently driving revenue growth. Biktarvy sales alone reached $13.42 billion in 2024, a 13.3% increase from the previous year. This strong cash flow from its core HIV business is crucial for funding the company's significant investments in its oncology pipeline and other therapeutic areas. The company is making a substantial bet on oncology, highlighted by its $21 billion acquisition of Immunomedics for the cancer drug Trodelvy and a recent $7.8 billion deal to acquire Arcellx. While Trodelvy's sales have been growing, hitting $1.3 billion in 2024, the drug has faced clinical trial setbacks in certain indications. The Arcellx acquisition gives Gilead full control over a promising CAR T-cell therapy, anito-cel, for multiple myeloma, with a potential FDA decision expected by December 23, 2026. In the cell and gene therapy space, Gilead's subsidiary Kite Pharma is a key player with its CAR T-cell therapies Yescarta and Tecartus. However, this portfolio has seen sales declines due to lower demand and competitive pressures. To counter this, Gilead is emphasizing manufacturing efficiency as a competitive advantage, aiming for faster turnaround times for these personalized therapies. The company is also exploring next-generation manufacturing processes to produce potentially better and more consistent CAR T products. CEO Daniel O'Day's compensation reached $23.7 million in 2024, a 5% increase from the previous year. His recent stock sales are part of a pre-arranged trading plan. Over the past year, O'Day has sold a total of 331,280 shares and has not made any purchases. Since he took the helm, Gilead's market cap has grown significantly, from $83 billion to $138 billion as of March 2025. Looking ahead, the biotech CDMO market, a key sector for companies like Gilead, is expected to see significant growth, projected to reach $55.11 billion by 2035. This growth is driven by the rise of complex modalities like cell and gene therapies and antibody-drug conjugates. However, the sector also faces challenges from biotech funding volatility and supply chain instability. Gilead's pipeline includes seven new candidates for HIV, with a focus on long-acting treatment and prevention options. The company is on track to deliver more than 10 transformative therapies by 2030 across virology, oncology, and inflammation. Upcoming milestones include potential new drug launches in 2026 and data from several late-stage trials.

Key numbers

• CEO Daniel O'Day recently sold nearly $1.5M in shares, a routine but noted move.
• Meanwhile, the company's foundation is awarding $12 million to community health programs, reinforcing its public health engagement.
• Biktarvy sales alone reached $13.42 billion in 2024, a 13.3% increase from the previous year.
• The company is making a substantial bet on oncology, highlighted by its $21 billion acquisition of Immunomedics for the cancer drug Trodelvy and a recent $7.8 billion deal to acquire Arcellx.

What happens next

• The Arcellx acquisition gives Gilead full control over a promising CAR T-cell therapy, anito-cel, for multiple myeloma, with a potential FDA decision expected by December 23, 2026.
• The company is also exploring next-generation manufacturing processes to produce potentially better and more consistent CAR T products.
• His recent stock sales are part of a pre-arranged trading plan.

Sources

• strong shareholder returns
• recently sold
• is awarding
• Gilead's financial landscape
• Biktarvy sales alone
• This strong cash flow
• While Trodelvy's sales
• The Arcellx acquisition
• In the cell and gene
• However, this portfolio
• To counter this, Gilead
• The company is also exploring
• CEO Daniel O'Day's compensation
• His recent stock sales
• Over the past year, O'Day
• Looking ahead, the biotech
• This growth is driven
• However, the sector also
• Gilead's pipeline includes
• The company is on track
• Upcoming milestones include

Quick answers